VolitionRx (VNRX) News Today $0.55 -0.02 (-4.13%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.56 +0.01 (+1.72%) As of 02/21/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)StockNews.com assumed coverage on shares of VolitionRx in a research note on Sunday. They set a "sell" rating on the stock.February 16, 2025 | marketbeat.comHead to Head Contrast: VolitionRx (NYSE:VNRX) vs. IDEXX Laboratories (NASDAQ:IDXX)February 14, 2025 | americanbankingnews.comVolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on VolitionRx in a research report on Saturday. They set a "sell" rating on the stock.February 8, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX)D. Boral Capital reissued a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research note on Thursday.February 6, 2025 | marketbeat.comVolition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosisFebruary 6, 2025 | prnewswire.comVolition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025February 5, 2025 | prnewswire.comStockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)StockNews.com initiated coverage on shares of VolitionRx in a research note on Friday. They issued a "sell" rating on the stock.January 31, 2025 | marketbeat.comVolitionRx’s Nu.Q NETs biomarker shows predictive power in sepsis studyJanuary 30, 2025 | markets.businessinsider.comLarge clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsisJanuary 30, 2025 | prnewswire.comVolitionRx's (VNRX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a research note on Wednesday.January 29, 2025 | marketbeat.comVolitionRx (NYSE:VNRX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a report on Wednesday.January 8, 2025 | marketbeat.comVolition Issues Business Review 2024January 8, 2025 | prnewswire.comVolitionRx (NYSE:VNRX) Now Covered by StockNews.comStockNews.com started coverage on VolitionRx in a research report on Tuesday. They set a "sell" rating for the company.January 7, 2025 | marketbeat.comVolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.comStockNews.com began coverage on VolitionRx in a research note on Monday. They issued a "sell" rating on the stock.December 30, 2024 | marketbeat.comVolitionRx Appoints LifeSci Advisors as Investor Relations ConsultantsDecember 12, 2024 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Insider Buys $24,903.87 in StockDecember 11, 2024 | insidertrades.comStudy shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screeningDecember 10, 2024 | prnewswire.comZacks Small Cap Expects Increased Earnings for VolitionRxVolitionRx Limited (NYSE:VNRX - Free Report) - Investment analysts at Zacks Small Cap upped their FY2024 EPS estimates for VolitionRx in a note issued to investors on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.28) per share for the year,December 9, 2024 | marketbeat.comVolitionRx Announces Pricing of up to $1.9 Million Registered Direct OfferingDecember 6, 2024 | prnewswire.comVolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on shares of VolitionRx in a research report on Thursday. They issued a "sell" rating for the company.November 28, 2024 | marketbeat.comBenchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX)Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday.November 22, 2024 | marketbeat.comVolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.comStockNews.com started coverage on VolitionRx in a research report on Wednesday. They set a "sell" rating on the stock.November 20, 2024 | marketbeat.comVolitionRx reports Q3 revenue up 187% year-over-year to $475KNovember 16, 2024 | markets.businessinsider.comVolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...November 16, 2024 | finance.yahoo.comVolitionRx Limited (VNRX) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comVolitionRx Limited Announces Third Quarter 2024 Financial Results and Business UpdateNovember 14, 2024 | prnewswire.comVolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business UpdateNovember 8, 2024 | prnewswire.comVolition Appoints Timothy I. Still as ChairmanNovember 6, 2024 | prnewswire.comMultiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deterioratingOctober 31, 2024 | prnewswire.comVolition to share new 'NETs in sepsis management' data insights at upcoming webinarOctober 9, 2024 | prnewswire.comVolition hosts NETs in sepsis management symposium at ESICM Lives 2024October 3, 2024 | prnewswire.comVolition Appoints Dr. Ethel Rubin as an Independent DirectorSeptember 30, 2024 | prnewswire.comVolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.comStockNews.com assumed coverage on shares of VolitionRx in a research report on Tuesday. They set a "sell" rating on the stock.September 17, 2024 | marketbeat.comVolition Hosts KOL Roundtable on SepsisSeptember 11, 2024 | prnewswire.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 150,000 Shares of StockAugust 22, 2024 | insidertrades.comVolitionRx Limited (VNRX) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comVolitionRx Limited Announces Second Quarter 2024 Financial Results and Business UpdateAugust 14, 2024 | prnewswire.comVolitionRX Q2 2024 Earnings PreviewAugust 14, 2024 | msn.comVolitionRx Announces Pricing of up to $21.5 Million Registered Direct OfferingAugust 9, 2024 | prnewswire.comVolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business UpdateAugust 6, 2024 | prnewswire.comVolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.comStockNews.com initiated coverage on VolitionRx in a report on Wednesday. They set a "sell" rating on the stock.July 31, 2024 | marketbeat.comVolition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensingJuly 9, 2024 | prnewswire.comVolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual MeetingJune 27, 2024 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Forecasted to Earn Q2 2024 Earnings of ($0.09) Per ShareVolitionRx Limited (NYSE:VNRX - Free Report) - Research analysts at Zacks Small Cap lifted their Q2 2024 earnings estimates for shares of VolitionRx in a research report issued to clients and investors on Tuesday, June 25th. Zacks Small Cap analyst S. Ralston now expects that the company will earJune 27, 2024 | marketbeat.comVolitionRx Limited to Present at Jefferies Global Healthcare ConferenceMay 29, 2024 | prnewswire.comCantor Fitzgerald Reiterates Overweight Rating for VolitionRx (NYSE:VNRX)Cantor Fitzgerald reissued an "overweight" rating and issued a $2.50 target price on shares of VolitionRx in a report on Thursday.May 16, 2024 | marketbeat.comVolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...May 15, 2024 | finance.yahoo.comVolitionRX: Q1 Earnings SnapshotMay 13, 2024 | washingtonpost.comVolitionRx Limited Announces First Quarter 2024 Financial Results and Business UpdateMay 13, 2024 | prnewswire.comVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateMay 8, 2024 | prnewswire.com Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Media Mentions By Week VNRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNRX News Sentiment▼0.300.60▲Average Medical News Sentiment VNRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNRX Articles This Week▼11▲VNRX Articles Average Week Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VYGR News DSGN News FDMT News LFCR News CCCC News CRDF News SLRN News LRMR News OCGN News GNFT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VNRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNRX Stock Alerts